Overview

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Status:
Not yet recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Genentech, Inc.
Seagen Inc.
Treatments:
Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab
Tucatinib